Get started
Author

Andreas Schröeder

Observed names: A. Schroeder, Andreas Schroeder
ORCID: 0000-0002-3568-1358
Observed ORCID: 0000-0002-3568-1358
OpenAlex ID: A5113937895
The RIN: an RNA integrity number for assigning integrity values to RNA measurements
2006 · Andreas Schroeder, Odilo Mueller, et al. · BMC Molecular Biology · 2,620
PDF
Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancer
2021 · Jean Bourhis, Alexander Stein, et al. · Cancer Treatment Reviews · 47
PDF
A phase Ib study of the anti-CD47 antibody magrolimab with the PD-L1 inhibitor avelumab (A) in solid tumor (ST) and ovarian cancer (OC) patients.
2020 · Nehal J. Lakhani, Amita Patnaik, et al. · Journal of Clinical Oncology · 37
First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma
2023 · Julius Strauss, Jean-Laurent Deville, et al. · Journal for ImmunoTherapy of Cancer · 29
PDF
The Justy mutation identifies Gon4-like as a gene that is essential for B lymphopoiesis
2010 · Ping Lu, Isaiah L. Hankel, et al. · The Journal of Experimental Medicine · 27
Evasion of apoptosis and treatment resistance in squamous cell carcinoma of the head and neck
2024 · Ben O’Leary, Heath Skinner, et al. · Cancer Treatment Reviews · 21
PDF
Inhibiting the inhibitors: Development of the IAP inhibitor xevinapant for the treatment of locally advanced squamous cell carcinoma of the head and neck
2022 · Robert L. Ferris, Kevin Harrington, et al. · Cancer Treatment Reviews · 21
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two
2016 · Casey Ager, Matthew Reilley, et al. · Journal for ImmunoTherapy of Cancer · 17
PDF
Abstract 2269: ATR inhibitor M6620 enhances anti-tumor efficacy of the combination of the anti-PD-L1 antibody avelumab with platinum-based chemotherapy
2019 · Marat Alimzhanov, Patricia Soulard, et al. · Cancer Research · 10
Model‐Informed Selection of the Recommended Phase III Dose of the Inhibitor of Apoptosis Protein Inhibitor, Xevinapant, in Combination with Cisplatin and Concurrent Radiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck
2023 · Yulia Vugmeyster, Abhigyan Ravula, et al. · Clinical Pharmacology & Therapeutics · 9
A randomized, double-blind, placebo-controlled, Phase I/II trial of RNActive®-vaccine cv9104 in patients with metastatic castrate-refractory prostate cancer (mcrpc): first results of the Phase I part
2014 · Sven D Koch, Henoch Hong, et al. · Journal for ImmunoTherapy of Cancer · 7
PDF
RNA integrity number (RIN) - towards standardization of RNA quality assessment
2004 · Odilo Mueller, Andreas Schröeder, et al. · Cancer Research · 4
103P First-line avelumab in combination with cetuximab and chemotherapy in patients with advanced squamous non-small cell lung cancer (NSCLC)
2021 · Z.G. Andric, G. Gálffy, et al. · Journal of Thoracic Oncology · 3
PDF
Randomized, phase Ib/II study of M6620 + avelumab + carboplatin vs standard care (sc) in patients (pts) with platinum-sensitive poly (ADP-ribose) polymerase inhibitor-(PARPi)-resistant ovarian cancer
2019 · S. Banerjee, I. Vergotte, et al. · Annals of Oncology · 3
Abstract 2269: ATR inhibitor M6620 enhances anti-tumor efficacy of the combination of the anti-PD-L1 antibody avelumab with platinum-based chemotherapy
2019 · Marat Alimzhanov, Patricia Soulard, et al. · Immunology · 3
Mucin 1 (MUC1) expression in patients (pts) with early stage non-small cell lung cancer (NSCLC): Relationship between immunohistochemistry (IHC), tumor characteristics, and survival.
2013 · Paul Leslie Mitchell, Shane Battye, et al. · Journal of Clinical Oncology · 2
Phase 2 study of xevinapant + chemoradiotherapy (CRT) vs placebo + CRT in patients with unresected locally advanced squamous cell carcinoma of the head and neck (LA SCCHN): A post hoc activity analysis by blinded independent review committee evaluation.
2024 · Jean Bourhis, S. Peter Eggleton, et al. · Journal of Clinical Oncology · 1
PDF
890P Real-world survival outcomes and survival risk factors in elderly patients with locally advanced squamous cell carcinoma of the head and neck
2023 · N.F. Saba, E. Lu, et al. · Annals of Oncology · 1
PDF
Avelumab in Combination With Cetuximab and Chemotherapy as First-Line Treatment for Patients With Advanced Squamous NSCLC
2023 · Zoran Andric, Gabriella Gálffy, et al. · JTO Clinical and Research Reports · 1
Abstract 5424: Selection of RP3D of xevinapant in combination with CRT in patients with LA SCCHN
2022 · Yulia Vugmeyster, Abhigyan Ravula, et al. · Cancer Research · 1
Abstract 964: Induction of immunogenic cell death and interferon signaling by carboplatin and the ATR inhibitor M6620 may contribute to anti-tumor activity of M6620-carboplatin-avelumab triplet combination in MC38 tumor model
2020 · Marat Alimzhanov, Ashwin George, et al. · Cancer Research · 1
Abstract CT140: A phase 1 study of the IAP inhibitor xevinapant (Debio 1143) to evaluate food effect and drug-drug interactions with a proton pump inhibitor in healthy volunteers
2024 · Valérie Nicolas-Métral, Elisabeth Rouits, et al. · Cancer Research
Adjusted RECIST Criteria for Assessing Time to Recurrence in Patients with Fully Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN)
2024 · S.P. Eggleton, M. O'Neal, et al. · International Journal of Radiation Oncology*Biology*Physics
Abstract CT191: Interim results from CLASSICAL-Lung, phase 1b/2 study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC
2020 · Jonathan W. Goldman, Terrence L. Fisher, et al. · Cancer Research
Abstract CT086: Interim results from CLASSICAL-Lung, a Phase Ib/II study of VX15/2503 (pepinemab) in combination with avelumab in advanced NSCLC
2019 · Michael Shafique, Terrence L. Fisher, et al. · Cancer Research
Works count: 27
Citation count: 2,863
H-index: 9
I10-index: 9
Year
Topic
Type